E6742, a dual TLR7/8 antagonist resulted in a suppression of the interferon gene signature responses, while showing promising preliminary efficacy signals in SLE patients in a phase 1/2 study (NCT05278663) (41). The gene discussed is TLR7; the disease is systemic lupus erythematosus.